Purpose: To evaluate the effectiveness of budesonide inhalation suspension relative to other common asthma therapies in a high-risk population, a study was conducted to compare the risk of having a ...
Sept. 5, 2003 — Caregivers of children treated with once or twice daily budesonide reported fewer limitations in daily activities and emotional functioning than caregivers of children treated with ...
Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in ...
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...
Teva announced the launch of Budesonide Inhalation Suspension, the generic version of AstraZeneca‘s Pulmicort Respules. Pulmicort Respules are indicated as maintenance treatment to control and prevent ...
Budesonide Inhalation Suspension, 0.5 mg/2 ml Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children from 12 months old to 8 years. Aurbodino ...
San Diego, Calif. – May 24, 2005 – Young children who are adherent with asthma controller therapies overall, and specifically PULMICORT RESPULES® (budesonide inhalation suspension), have lower ...
Research and Markets: Investigation Report on China's Budesonide (Pulmicort Respules) Market to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results